<?xml version='1.0' encoding='utf-8'?>
<document id="28916286"><sentence text="Toxicology studies of primycin-sulphate using a three-dimensional (3D) in vitro human liver aggregate model."><entity charOffset="22-39" id="DDI-PubMed.28916286.s1.e0" text="primycin-sulphate" /></sentence><sentence text="Primycin-sulphate is a highly effective compound against Gram (G) positive bacteria"><entity charOffset="0-17" id="DDI-PubMed.28916286.s2.e0" text="Primycin-sulphate" /></sentence><sentence text=" It has a potentially synergistic effect with vancomycin and statins which makes primycin-sulphate a potentially very effective preparation"><entity charOffset="46-56" id="DDI-PubMed.28916286.s3.e0" text="vancomycin" /><entity charOffset="81-98" id="DDI-PubMed.28916286.s3.e1" text="primycin-sulphate" /><pair ddi="false" e1="DDI-PubMed.28916286.s3.e0" e2="DDI-PubMed.28916286.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28916286.s3.e0" e2="DDI-PubMed.28916286.s3.e1" /></sentence><sentence text=" Primycin-sulphate is currently used exclusively in topical preparations"><entity charOffset="1-18" id="DDI-PubMed.28916286.s4.e0" text="Primycin-sulphate" /></sentence><sentence text=" In vitro animal hepatocyte and neuromuscular junction studies (in mice, rats, snakes, frogs) as well as in in vitro human red blood cell experiments were used to test toxicity" /><sentence text=" During these studies, the use of primycin-sulphate resulted in reduced cellular membrane integrity and modified ion channel activity"><entity charOffset="34-51" id="DDI-PubMed.28916286.s6.e0" text="primycin-sulphate" /></sentence><sentence text=" Additionally, parenteral administration of primycin-sulphate to mice, dogs, cats, rabbits and guinea pigs indicated high level of acute toxicity"><entity charOffset="44-61" id="DDI-PubMed.28916286.s7.e0" text="primycin-sulphate" /></sentence><sentence text=" The objective of this study was to reveal the cytotoxic and gene expression modifying effects of primycin-sulphate in a human system using an in vitro, three dimensional (3D) human hepatic model system"><entity charOffset="98-115" id="DDI-PubMed.28916286.s8.e0" text="primycin-sulphate" /></sentence><sentence text=" Within the 3D model, primycin-sulphate presented no acute cytotoxicity at concentrations 1Î¼g/ml and below"><entity charOffset="22-39" id="DDI-PubMed.28916286.s9.e0" text="primycin-sulphate" /></sentence><sentence text=" However, even at low concentrations, primycin-sulphate affected gene expressions by up-regulating inflammatory cytokines (e"><entity charOffset="38-55" id="DDI-PubMed.28916286.s10.e0" text="primycin-sulphate" /></sentence><sentence text="g" /><sentence text=", IL6), chemokines (e" /><sentence text="g" /><sentence text=", CXCL5) and by down-regulating molecules of the lipid metabolism (e" /><sentence text="g" /><sentence text=", peroxisome proliferator receptor (PPAR) alpha, gamma, etc)" /><sentence text=" Down-regulation of PPAR alpha cannot just disrupt lipid production but can also affect cytochrome P450 metabolic enzyme (CYP) 3A4 expression, highlighting the need for extensive drug-drug interaction (DDI) studies before human oral or parenteral preparations can be developed" /><sentence text="" /></document>